China In-Licensing Crossroads: Zai Lab, Everest March Towards Market But BioNova Returns Rights

 
• By Dexter Jie Yan

China's Zai Lab and Everest are still pursuing profitability on the commercialization of in-licensed assets, while BioNova and others have already bowed out of the game.

in-licensing at a crossroads
Amid funding crunch, Chinese in-licensing players reach crossroads toward commercialization • Source: Shutterstock

More from China

More from Focus On Asia